Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV000677504 | SCV002021449 | likely pathogenic | Mucopolysaccharidosis type 6 | 2021-07-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000677504 | SCV003525875 | pathogenic | Mucopolysaccharidosis type 6 | 2022-07-05 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant results in an extension of the ARSB protein. Other variant(s) that result in a similarly extended protein product (p.*534Serext*50 and p.*534Glnext*50) have been determined to be pathogenic (PMID: 8144552; Invitae). This suggests that these extensions are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 559729). This variant is also known as p.*534W. This variant has been observed in individual(s) with mucopolysaccharidosis type VI (PMID: 26909334, 30524696). This variant is not present in population databases (gnomAD no frequency). This sequence change results in a frameshift in the ARSB gene (p.*534Trpext*50). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last amino acid(s) of the ARSB protein and extend the protein by 50 additional amino acid residues |
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000677504 | SCV000803014 | uncertain significance | Mucopolysaccharidosis type 6 | 2018-01-01 | flagged submission | curation | Absent from GnomAD (PM2); Protein length changes as a result of a stop-loss variant (PM4) |